McKesson Again Boosts Outlook After 2Q Revenue Jumps 10%

Dow Jones

11/06

By Paul Ziobro

McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products.

The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago.

Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share.

Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its North American pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost.

The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items.

McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

November 05, 2025 16:56 ET (21:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581001117"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581001117\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581001117?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581001117","market":"sh","top_or_hot":-1,"title":"McKesson Again Boosts Outlook After 2Q Revenue Jumps 10%","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products. \n</p>\n<p>\n  The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago. \n</p>\n<p>\n  Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share. \n</p>\n<p>\n  Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its <a href=\"https://laohu8.com/S/FNCSF\">North American</a> pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost. \n</p>\n<p>\n  The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items. \n</p>\n<p>\n  McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2025 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>McKesson Again Boosts Outlook After 2Q Revenue Jumps 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMcKesson Again Boosts Outlook After 2Q Revenue Jumps 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-06 05:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products. \n</p>\n<p>\n  The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago. \n</p>\n<p>\n  Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share. \n</p>\n<p>\n  Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its <a href=\"https://laohu8.com/S/FNCSF\">North American</a> pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost. \n</p>\n<p>\n  The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items. \n</p>\n<p>\n  McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 05, 2025 16:56 ET (21:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MCK","symbol_name":"麦克森药物批发","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2581001117","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581001117","pubTimestamp":1762379760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products.The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago.Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share.Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its North American pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost.The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items.McKesson now expect","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MCK":"麦克森药物批发"},"translate_title":"McKesson在第二季度收入增长10%后再次上调前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCK":1.5},"content_text":"By Paul Ziobro \n\n\n \n\n\n  McKesson again raised its adjusted profit outlook for the year after revenue rose 10% in the second quarter, boosted by higher prescription volumes and growth in distribution of oncology and multispecialty products. \n\n\n  The pharmaceutical distributor on Wednesday reported a profit of $1.11 billion, or $8.92 a share, compared with $241 million, or $1.87 a share, a year ago. \n\n\n  Adjusted earnings were $9.86 a share. Analysts polled by FactSet expected $9.03 a share. \n\n\n  Revenue rose about 10% to $103.15 billion, short of analyst estimates for $104.14 billion. The company said growth was led by its North American pharmaceutical segment, where it logged more prescription volumes. Acquisitions in its Oncology and Multispecialty segment also provided a boost. \n\n\n  The company said its bottom-line boost came from operational growth across its businesses, including contributions from acquisitions, the sale of an investment and market decisions within the U.S. Oncology Network, among other items. \n\n\n  McKesson now expects adjusted per-share earnings between $38.35 and $38.85, compared to its prior view of $38.05 to $38.55. \n\n\n \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 16:56 ET (21:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}